In a significant advancement for endometriosis diagnosis, Serac Healthcare, in collaboration with the University of Oxford, has presented new data showcasing the effectiveness of 99mTc-maraciclatide in imaging the earliest stage of the disease. The DETECT study’s findings, presented by Dr. Tatjana Gibbons at the European Endometriosis Congress, reveal the agent’s potential as a non-invasive diagnostic tool. The study involved imaging the first ten patients with suspected endometriosis using a SPECT-CT camera, followed by laparoscopic surgery to confirm the presence and location of endometriotic lesions. The imaging results aligned with surgical and histological reports, suggesting that 99mTc-maraciclatide could accurately identify superficial peritoneal endometriosis, which accounts for approximately 80% of all diagnoses and is typically only detectable through surgery. David Hail, CEO of Serac Healthcare, expressed optimism about the findings: “The promising initial findings have been further confirmed by more patients in this study indicating the very exciting possibility that maraciclatide has ...
The Polymerase Chain Reaction (PCR) is widely regarded as the definitive method for target DNA sequence amplification, testing, and analysis. In this traditional PCR process, the DNA sample undergoes heating to separate into single strands, which then serve as templates for synthesizing new DNA strands through enzymatic action. Despite its effectiveness, this method can be cumbersome, slow, and costly. Now, researchers have introduced an alternative DNA testing method that could potentially replace traditional PCR, paving the way for broader applications in medical diagnostics. Developed at Case Western Reserve University (Cleveland, OH, USA), this new technique or reaction is named AMPLON (Amplifying DNA with Multiarm Priming and Looping Optimization of Nucleic Acid). It enables comparison of DNA from diseased cells with that from healthy ones, enhancing understanding of disease progression and treatment approaches. AMPLON uses multiple extensions along the DNA strand, significantly enhancing the speed and accuracy of DNA synthesis at ...
Researchers have unveiled a groundbreaking method to detect cancer, potentially simplifying the process to just taking a blood test. This technique, which boasts a 98.7% accuracy rate, combines optical imaging technology with fluorescent imaging. The method’s capability to identify cancer at its initial stages could significantly enhance the effectiveness of treatments. The highly accurate method developed by a research team at the University of Houston (Houston, TX, USA) enables the examination of extracellular vesicles or EVs—nanometer-sized membrane sacs present in the bloodstream that can transport various cargoes, including proteins, nucleic acids, and metabolites. In 2020, the research team introduced PANAROMA, an optical imaging technology featuring a glass slide covered with gold nanodiscs. This setup permits the observation of light transmission changes and the determination of nanoparticles as small as 25 nanometers in diameter. The technology’s name, PANORAMA, stands for Plasmonic Nano-aperture Label-free Imaging, highlighting its critical features. For this particular ...
Currently, the prostate-specific antigen (PSA) test is widely used to identify men who are at an increased risk of prostate cancer based on factors like age and ethnicity, as well as those showing symptoms. Elevated PSA levels may indicate prostate cancer, prompting further investigations such as MRI scans, biopsies, and treatments. However, the PSA test often results in false positives—incorrectly indicating prostate cancer in three out of four instances. It also detects cancers that grow so slowly they are unlikely to pose a significant health threat, leading to potentially unnecessary medical procedures. Now, a saliva-based test that individuals can perform at home has proven better at predicting the risk of developing prostate cancer than the traditional blood test. Researchers from The Institute of Cancer Research (London, UK) and The Royal Marsden NHS Foundation Trust (London, UK) conducted a trial of this innovative DNA test that screens for genetic variants associated ...
Wearable bioelectronics has emerged as a significant innovation in healthcare, especially in the field of biosensing, providing a new method to monitor individual health for both diagnostic and therapeutic purposes. Despite its advancements, there has been a lack of progress specifically in the area of cancer, and more notably in skin cancer detection. Researchers have now introduced a novel technique for identifying malignant melanoma, which is the most serious type of skin cancer and also the fastest growing. A groundbreaking study conducted by researchers at Karolinska Institutet (Stockholm, Sweden) led to the development of a new type of patch equipped with microneedles designed to detect the biomarker tyrosinase directly within the skin. Tyrosinase is an enzyme that serves as a crucial biomarker for malignant melanoma. By assessing the enzyme directly in the skin, this approach allows for the rapid detection of changes indicative of the disease. The feasibility of this ...
The proposals will help MedTech developers access NHS funding to fast-track products NHS England and the National Institute for Health and Care Excellence (NICE) have announced a new plan to adopt innovative medical technologies to provide faster access to NICE-recommended products and improve patient outcomes. The proposals set out a route for MedTech developers to access NHS funding to fast-track clinically and cost-effective products to be used by NHS England. Developed by NHS England and NICE with input from the Department of Health and Social Care, as well as other partners including the Office for Life Science and the Medicines and Healthcare products Regulatory Agency, the new plans will also support MedTech innovators and suppliers with automatic funding to support routine commissioning for technologies that meet the required criteria. NHS England’s interim medical director for transformation, Dr Vin Diwaker, said: “Medical technology plays a vital role in the nation’s health ...
According to the Heart Failure Society of America, nearly 6.5 million Americans over the age of 20 suffer from heart failure, which accounts for about 8.5% of all heart disease deaths in the United States. A new assay now aids in diagnosing individuals who are suspected of having acute heart failure in emergency departments, as well as in evaluating the severity and risk stratification of patients with heart failure and acute coronary syndrome. The Access NT-proBNP (N-terminal Pro B-type Natriuretic Peptide) assay from Beckman Coulter (Brea, CA, USA) measures the levels of N-terminal pro B-type natriuretic peptide in serum or plasma that is released in the heart. Elevated levels of these peptides may indicate heart failure. As per the latest heart failure guidelines issued by the American College of Cardiology and the American Heart Association, the Access NT-proBNP assay includes age-based cutoffs to aid in the accurate diagnosis of heart ...
Traumatic brain injury (TBI) occurs when external mechanical energy is transferred to brain tissue, causing cellular damage, dysfunction, and dysregulation. It is a significant public health issue, being a leading cause of death and disability globally, with approximately 69 million people affected each year. For clinicians assessing these patients, it is crucial to quickly ascertain the presence or absence of potentially life-threatening hemorrhages and neurological complications. TBI severity is evaluated using the Glasgow Coma Scale (GCS) and categorized as mild, moderate, or severe. Mild traumatic brain injuries (mTBI) are the most common, comprising 70-90% of all TBI cases, and they are the least likely to lead to acute medical emergencies. It is noted that about 90% of mTBI patients who receive computed tomography (CT) scans show no abnormal findings. Despite this, an estimated 82% of all TBI patients are scanned, many of which could potentially be unnecessary. These scans not ...
Bone marrow transplant, also referred to as hematopoietic cell transplantation (HCT), serves as a critical treatment for children with leukemia, bone marrow failure, and various genetic disorders, including inborn immunodeficiencies and sickle-cell disease. However, the procedure is intense, involving high doses of chemotherapy to eradicate diseased cells in the bone marrow. This treatment suppresses the immune system to allow healthy stem cells to grow, which are then transplanted into the patients. Due to this immune suppression, patients become highly susceptible to viruses, bacteria, and other pathogens during the critical phase when their immune system is “rebooting.” Lung infections are especially prevalent among these patients, affecting up to 40% of pediatric HCT recipients. When these infections require ventilator support, the mortality rate can be as high as 50%. Identifying the specific pathogens involved is challenging because doctors using conventional diagnostic tests may not be able to target the correct ones, given ...
Nephrotic syndrome is associated with several kidney diseases such as minimal change disease (MCD), primary focal segmental glomerulosclerosis (FSGS), and membranous nephropathy (MN), and is characterized by high levels of protein in the urine. This condition primarily stems from damage to podocytes, the cells that filter blood in the kidneys, which results in protein leakage into the urine. Often, children diagnosed with MCD or FSGS are categorized under idiopathic nephrotic syndrome (INS), indicating an unknown cause. This is typically because children with elevated urinary protein levels seldom undergo kidney biopsies, which are the standard method for determining the underlying cause. Traditionally, the diagnosis of these conditions has been complicated due to their similar histological features and a general reluctance to perform invasive kidney biopsies, especially in children. Although anti-nephrin autoantibodies have been detected in some patients with MCD and FSGS, their exact role in the progression of these diseases remains ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.